Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
N/A
GROSS MARGIN AVG 3Y
N/A
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
42.91%
median of 588 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Eikon Therapeutics, Inc. Common Stock
Market Cap
$411.99M
Gross Margin
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$412.27M
Gross Margin
68.83%
TTM Avg
69.91%
3Y Avg
69.67%
5Y Avg
69.68%
Market Cap
$407.09M
Gross Margin
77.34%
TTM Avg
76.74%
3Y Avg
77.57%
5Y Avg
77.57%
Market Cap
$406.54M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
12.37%
Market Cap
$402.01M
Gross Margin
0.00%
TTM Avg
-125.52%
3Y Avg
-62.76%
5Y Avg
-41.84%
Market Cap
$425.86M
Gross Margin
100.00%
TTM Avg
-208.30%
3Y Avg
-64.13%
5Y Avg
-41.74%
Market Cap
$432.69M
Gross Margin
0.00%
TTM Avg
-62.19%
3Y Avg
-231.05%
5Y Avg
-120.70%
Market Cap
$437.27M
Gross Margin
99.82%
TTM Avg
1.85%
3Y Avg
-144.74%
5Y Avg
-84.51%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eikon Therapeutics, Inc. Common Stock (EIKN) | $411.99M | 0.00% | N/A | N/A | N/A |
| Myriad Genetics, Inc. (MYGN)vs › | $412.27M | 68.83% | 69.91% | 69.67% | 69.68% |
| Carlsmed, Inc. (CARL)vs › | $408.32M | 76.63% | 74.56% | 73.66% | 73.66% |
| Shoulder Innovations, Inc. (SI)vs › | $407.09M | 77.34% | 76.74% | 77.57% | 77.57% |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $406.54M | 0.00% | 0.00% | 0.00% | 12.37% |
| Neurogene Inc. (NGNE)vs › | $402.01M | 0.00% | -125.52% | -62.76% | -41.84% |
| Editas Medicine, Inc. (EDIT)vs › | $425.86M | 100.00% | -208.30% | -64.13% | -41.74% |
| Capricor Therapeutics, Inc. (CAPR)vs › | $432.69M | 0.00% | -62.19% | -231.05% | -120.70% |
| Assembly Biosciences, Inc. (ASMB)vs › | $437.27M | 99.82% | 1.85% | -144.74% | -84.51% |
| MapLight Therapeutics, Inc. (MPLT)vs › | $384.04M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
